Retatrutide has not been approved by the MHRA and is not available from regulated UK pharmacies, online doctors or private weight loss clinics
Many GLP-1s are FDA approved for more than just weight loss, including type 2 diabetes, cardiovascular risk reduction, and even stroke prevention in certain populations, says Supriya Rao, MD, an obesity physician and the director of medical weight loss at Lowell General Hospital in Lowell, Massachusetts
In the meantime, the evidence supports a straightforward approach: start low, escalate slowly, monitor regularly, and evaluate heart rate changes in the context of overall cardiovascular health rather than as an isolated number
Bottom line Retatrutide is still in clinical trials, with early data suggesting significant weight loss potential, while tirzepatide has FDA approval and proven efficacy and safety history
Glucagon-like peptide-1 Glucagon-like peptide-1 ( GLP-1 ) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide
Retatrutide Chemical Identity Retatrutide is a synthetic peptide analog that is structurally derived from the glucagon peptide family and engineered to interact with multiple incretin related receptor systems
